uniQureQURE
QURE
About: uniQure NV is a gene therapy company. It develops treatments and platforms for patients suffering from genetic and other devastating diseases. Its products and services are focused on hemophilia, Huntington's disease, and cardiovascular diseases. The company is focused on the development of the pipeline of gene therapies with the collaboration of Bristol Myers Squibb for cardiovascular diseases.
Employees: 480
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 8 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 16
51% more call options, than puts
Call options by funds: $4.99M | Put options by funds: $3.31M
21% more capital invested
Capital invested by funds: $162M [Q2] → $195M (+$33.2M) [Q3]
12% more funds holding
Funds holding: 116 [Q2] → 130 (+14) [Q3]
6.41% more ownership
Funds ownership: 74.48% [Q2] → 80.89% (+6.41%) [Q3]
10% less repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 40
Research analyst outlook
8 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$20
34%
upside
Avg. target
$34
131%
upside
High target
$58
289%
upside
8 analyst ratings
6 positive
75%
2 neutral
25%
0 negative
0%
RBC Capital Luca Issi 17% 1-year accuracy 10 / 60 met price target | 61%upside $24 | Outperform Reiterated | 21 Jan 2025 |
Mizuho Uy Ear 40% 1-year accuracy 4 / 10 met price target | 34%upside $20 | Neutral Maintained | 19 Dec 2024 |
Stifel Paul Matteis 14% 1-year accuracy 2 / 14 met price target | 115%upside $32 | Buy Maintained | 16 Dec 2024 |
Goldman Sachs Salveen Richter 19% 1-year accuracy 3 / 16 met price target | 34%upside $20 | Neutral Maintained | 12 Dec 2024 |
Leerink Partners | 195%upside $44 | Outperform Maintained | 11 Dec 2024 |
Financial journalist opinion
Based on 3 articles about QURE published over the past 30 days
Neutral
GlobeNewsWire
1 week ago
uniQure Announces Pricing of its Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 08, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its underwritten public offering of 4,411,764 of its ordinary shares at a public offering price of $17.00 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $75 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-day option to purchase up to 661,764 additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about January 10, 2025, subject to the satisfaction of customary closing conditions.
Neutral
GlobeNewsWire
2 weeks ago
uniQure Announces Proposed Public Offering
LEXINGTON, Mass. and AMSTERDAM, Jan. 07, 2025 (GLOBE NEWSWIRE) -- uniQure N.V. (Nasdaq: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced an underwritten public offering of its ordinary shares and pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to 15% additional ordinary shares at the public offering price, less underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Neutral
CNBC Television
3 weeks ago
Final Trade: DVN, QURE, GOOGL, DFH
The final trades of the day with the Fast Money traders.
Positive
The Motley Fool
1 month ago
Up 152% in December, Is uniQure a Good Stock to Buy Now and Hold Through 2025?
Shares of the international gene therapy developer uniQure (QURE 2.26%) have been soaring. Investors are responding to positive news regarding the Food and Drug Administration (FDA) and the company's Huntington's disease candidate.
Positive
Zacks Investment Research
1 month ago
QURE Soars on FDA Alignment for Speedy Approval of Huntington's Drug
uniQure stock rallies 110% on reaching alignment with the FDA on key elements of an accelerated approval pathway for AMT-130 to treat Huntington's disease.
Positive
Investors Business Daily
1 month ago
UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug
UniQure stock nearly doubled Tuesday after the company reached a testing agreement with the FDA for its Huntington's disease treatment. The post UniQure Stock Nearly Doubles After Striking A Deal With The FDA For Huntington's Drug appeared first on Investor's Business Daily.
Neutral
GlobeNewsWire
1 month ago
uniQure Announces Alignment with FDA on Key Elements of Accelerated Approval Pathway for AMT-130 in Huntington's Disease
~ U.S. Food and Drug Administration (FDA) agrees that data from ongoing Phase I/II studies compared to a natural history external control may serve as the primary basis for a Biologics License Application (BLA) for Accelerated Approval ~
Positive
Zacks Investment Research
1 month ago
Wall Street Analysts Think uniQure (QURE) Could Surge 228.07%: Read This Before Placing a Bet
The consensus price target hints at a 228.1% upside potential for uniQure (QURE). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
1 month ago
What Makes uniQure (QURE) a New Buy Stock
uniQure (QURE) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Neutral
GlobeNewsWire
2 months ago
uniQure Announces Dosing of First Patient in GenTLE Phase I/IIa Clinical Trial of AMT-260 for the Treatment of Refractory Mesial Temporal Lobe Epilepsy
LEXINGTON, Mass. and AMSTERDAM, Nov. 21, 2024 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that the first patient has been dosed in the GenTLE Phase I/IIa clinical trial of AMT-260 for the treatment of refractory mesial temporal lobe epilepsy (MTLE).
Charts implemented using Lightweight Charts™